Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c in HER2-expressing unresectable locally advanced, recurrent or metastatic gastric cancer
CTR20210829Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DP303c in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by CSPC Pharmaceutical Group. Started Apr 2021; status: terminated.
02
Drugs
DP303c
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20210829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210829.